RBC Capital analyst Gregory Renza raised the firm’s price target on CorMedix (CRMD) to $22 from $21 and keeps an Outperform rating on the shares. CorMedix raised their pro-forma 2025 revenue guidance to $375M+ and reported an $85M+ quarter for DefenCath, showing strong quarter over quarter growth for DefenCath, the analyst tells investors in a research note. DefenCath still has room to grow within existing dialysis organizations and the post-TDAPA cliff is manageable, the firm argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Cormedix’s Strong Financial Performance and Promising Prospects Drive Buy Rating
- Midday Fly By: AWS hit by outage, Kering sells beauty unit
- Morning Movers: Cleveland-Cliffs surges following earnings report
- CorMedix upgraded to Buy from Hold at D. Boral Capital
- CorMedix reports preliminary Q3 unaudited net revenue more than $100M